类风湿关节炎缓解与低疾病活动度的频率及其识别低残疾和正常生活质量的能力
该研究基于两项临床试验的571例患者和10年常规诊疗队列的1693例患者,评估类风湿关节炎中缓解与低疾病活动度(LDA)的频率、持续性,以及二者识别低残疾(HAQ≤0.5)和正常健康相关生活质量(HRQoL,EQ-5D≥正常人群)的能力。结果显示点缓解和缓解/LDA常见但持续维持者少,缓解对低残疾和正常HRQoL高度特异但敏感性不足,最佳DAS28-ESR截点约在LDA阈值附近。
要点
- 点缓解和缓解/LDA常见,但持续缓解和持续缓解/LDA分别仅5-9%和9-16%。
- 缓解识别低残疾特异性85-91%但敏感性51-57%,识别正常HRQoL特异性78-86%但敏感性52-59%。
- 识别低残疾和正常HRQoL的最佳DAS28截点约在LDA阈值附近,DAS28-ESR≤3.2平衡更佳且更易达到。
核心结论
- 研究结果支持达标治疗中缓解和LDA两个目标,达到缓解对低残疾和正常HRQoL高度特异,但许多疾病活动度较高的患者也有良好功能和生活质量。
- 达到DAS28-ESR≤3.2在识别低残疾和正常HRQoL方面特异性和敏感性平衡更好,且更易实现。
- 尽管持续维持这些目标少见,但即使一次性达到也能为患者带来更好的功能和生活质量结局。
研究设计与样本
- 研究纳入两项临床试验的571例患者和10年常规诊疗队列的1693例患者。
- 评估缓解和缓解/LDA的频率与可持续性、缓解后DAS28-ESR的变异性,并使用受试者工作特征(ROC)曲线分析缓解和缓解/LDA识别低残疾和正常HRQoL的敏感性/特异性。
主要发现
- 点缓解和缓解/LDA分别由35-58%和49-74%的患者达到,但持续缓解和持续缓解/LDA仅由5-9%和9-16%的患者达到。
- 达到缓解后DAS28-ESR水平变化较大,但在达到点缓解的患者中多数(53-61%)在研究终点时仍处于缓解。
- 缓解识别低残疾的特异性为85-91%、敏感性为51-57%;识别正常HRQoL的特异性为78-86%、敏感性为52-59%。
- 识别低残疾和正常HRQoL的最佳DAS28截点约在LDA阈值附近。
关键数值与推荐
- 低残疾定义为HAQ≤0.5,正常HRQoL定义为EQ-5D≥正常人群。
- 点缓解和缓解/LDA分别由35-58%和49-74%的患者达到,持续缓解和持续缓解/LDA分别由5-9%和9-16%的患者达到。
- 缓解识别低残疾特异性85-91%、敏感性51-57%;识别正常HRQoL特异性78-86%、敏感性52-59%。
- 达到DAS28-ESR≤3.2在识别低残疾和正常HRQoL方面特异性和敏感性平衡更好。
临床怎么用
- 达标治疗可选择缓解或LDA作为目标,二者均被研究结果支持。
- DAS28-ESR≤3.2可作为识别低残疾和正常HRQoL的合理截点,且比缓解更易达到。
- 即使未能持续维持缓解或LDA,一次性达到目标仍与更好的功能和生活质量相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treat-to-target in rheumatoid arthritis (RA) recommends targeting remission, with low disease activity (LDA) being an alternative goal. When deciding to target remission or LDA, important considerations are the likelihood of attaining them, and their impacts on function and health-related quality of life (HRQoL). We have addressed this by studying: (a) the frequency of remission and LDA/remission; (b) DAS28-ESR trends after remission; (c) ability of remission vs. LDA to identify patients with normal function (HAQ ≤ 0.5) and HRQoL (EQ-5D ≥ the normal population). METHODS: We studied 571 patients in two clinical trials, and 1693 patients in a 10-year routine care cohort. We assessed the frequency and sustainability of remission and LDA/remission, variability in DAS28-ESR after remission, and sensitivity/specificity of remission and LDA/remission at identifying patients with low disability levels and normal HRQoL using Receiver Operator Characteristic (ROC) curves. RESULTS: Point remission and remission/LDA were common (achieved by 35-58% and 49-74% of patients, respectively), but were rarely sustained (sustained remission and remission/LDA achieved by 5-9% and 9-16% of patients, respectively). Following attaining remission, DAS28-ESR levels varied substantially. Despite this, of those patients attaining point remission, the majority (53-61%) were in remission at study end-points. Whilst remission was highly specific at identifying patients with low disability (85-91%) it lacked sensitivity (51-57%); similar findings were seen for normal HRQoL (specificity 78-86%; sensitivity 52-59%). The optimal DAS28-cut-off to identify individuals with low disability and normal HRQoL was around the LDA threshold. CONCLUSIONS: Our findings support both the treat-to-target goals. Attaining remission is highly specific for attaining low disability and normal HRQoL, although many patients with more active disease also have good function and HRQoL. Attaining a DAS28-ESR ≤ 3.2 has a better balance of specificity and sensitivity for attaining these outcomes, with the benefit of being more readily achievable. Although sustaining these targets over time is rare, even attaining them on a one-off basis leads to better function and HRQoL outcomes for patients.
引用
- Scott IC, Ibrahim F, Panayi G, et al. The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life. Semin Arthritis Rheum. 2018. PMID: 30685064. doi:10.1016/j.semarthrit.2018.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。